Good AI Capital

Aether Bio is a technology company that focuses on re-purposing enzymes to create new compounds using machine learning. By integrating machine learning with high-throughput robotic laboratories, Aether Bio engineers enzymes rapidly and enables massively parallelized experimentation. This innovative approach generates significantly larger datasets compared to competitors, allowing researchers to manufacture complex and novel products more efficiently and at a lower cost. The company's technology aims to provide healthcare institutions with sustainable and affordable chemicals and materials essential for their operations.

Serve Robotics designs and operates autonomous, zero‑emission robotic carriers that deliver food and other goods in public spaces. The company builds an AI‑powered mobility platform to support last‑mile delivery in urban environments and partners with merchants and delivery platforms to extend local businesses’ reach.

Pragma Bio is a biotechnology company that uses microbiome-based approaches to discover therapies for cancer and autoimmune diseases, combining genomic sequencing, artificial intelligence, and synthetic biology to identify biomarkers and develop therapeutics through a data-driven platform that aggregates public and private data to build a microbiome database and reveal connections across microbial and clinical data. The company pursues small-molecule discovery from human-associated bacteria, focusing on the gut-immune axis, and aims to deliver health-indicative molecules with robust safety profiles, while the platform supports risk stratification and outcome prediction for patients by leveraging real-world data. Pragma Bio was founded in 2018 in Millbrae, California by Peter McCaffrey, Kovi Bessoff, Ayin Vala and Kareem Barghouti.

Stellic Inc. is an innovative company that operates an integrated planning and advising platform aimed at enhancing the academic experience for students. The platform features tools such as Degree Planner, which assists students in selecting courses and planning their semesters, while also providing features like prerequisite checks and integrated calendars. Additionally, the Degree Audit tool helps students track their academic progress by calculating completed, in-progress, and remaining requirements. The Advisor Tool empowers advisors to identify at-risk students early on, facilitating timely interventions. Furthermore, Stellic offers Data Reports that provide university administrators with insights into course demand, student performance challenges, and overall engagement. Founded by Carnegie Mellon undergraduates, the company emerged from a desire to improve the degree planning process, and it has since garnered recognition within the academic community. Stellic Inc. is headquartered in Doha, Qatar, with an additional location in Palo Alto, California.

Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

Founded in 2017, Mekonos specializes in the development of gene and cell therapies. The company designs integrated system-on-a-chip technology to create predictive models for discovery and development, and operates a proprietary cell-engineering platform based on scalable silicon technology.

Playco Global, Inc. is a gaming company that specializes in developing an instant-play gaming platform, enabling multiplayer experiences accessible to billions of users without the need for downloads. Founded in 2010 and based in Mountain View, California, with additional offices in San Francisco, Tokyo, and Seoul, Playco has created a browser-based streaming game engine that allows users to enjoy advanced games across various gaming platforms. The company collaborates with a wide range of partners, from major tech and social media companies to emerging startups, to develop innovative gaming technologies. Playco's focus on seamless multiplayer interactions positions it as a leader in the evolution of social gaming.

Keatext is a Montreal-based technology company that provides an AI-powered text analytics platform to synthesize customer feedback from multiple channels including surveys, online reviews, chat logs, social media, and support tickets. Using natural language processing, the platform consolidates data into a single view to surface actionable insights, helping businesses understand what customers care about, identify improvement opportunities, and make data-driven decisions to enhance customer experience and related outcomes.

Founded in 2017, Mekonos specializes in the development of gene and cell therapies. The company designs integrated system-on-a-chip technology to create predictive models for discovery and development, and operates a proprietary cell-engineering platform based on scalable silicon technology.

UpLift, Inc. is a fintech company based in Menlo Park, California, founded in 2011. The company specializes in digital lending solutions for the travel industry, offering buy now, pay later services that allow consumers to finance their travel bookings through flexible payment plans. UpLift partners with over 100 leading travel brands to provide personalized payment options, enabling customers to budget more effectively while enhancing their travel experiences. By facilitating payments in monthly installments, UpLift aims to make travel more accessible and affordable, thereby increasing conversion rates and customer loyalty for its merchant partners.

Persist AI is a company that aids pharmaceutical firms in the development of long-acting drug formulations by leveraging artificial intelligence and automation. Traditional formulation development is a lengthy process, typically spanning 5 to 10 years, which includes extensive pre-clinical and clinical testing phases. Persist AI aims to significantly reduce this timeline by streamlining pre-clinical formulation development to just three months, enhancing the efficiency of the drug development process by 50%. The company employs AI-driven automation technologies, such as automated drug release testing and high-throughput formulation screening, to facilitate quicker and more reliable drug formulation. By doing so, Persist AI not only accelerates drug development but also contributes to improving patient outcomes.